Eyenovia found using ticker (EYEN) have now 3 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 19 and 6 and has a mean target at 12. Now with the previous closing price of 6.96 this would indicate that there is a potential upside of 72.4%. The 50 day moving average now sits at 4.94 and the 200 day MA is 3.8. The market capitalisation for the company is $170m. You can visit the company’s website by visiting: http://www.eyenoviabio.com
Eyenovia, a clinical stage ophthalmic biopharmaceutical company, engages in developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, branded the Optejet. It focuses on achieving clinical microdosing of next-generation formulations of ophthalmic pharmaceutical agents using its ocular delivery system, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. The company, through its proprietary delivery technology, is developing smart ophthalmic therapies while targeting new indications for which there are currently no drug therapies approved by the U.S. Food and Drug Administration. Eyenovia focuses on advancing its MicroLine program for the improvement in near vision in patients with presbyopia in Phase III development. Its other product candidates include MicroProst, which is in Phase III clinical trials for the treatment of chronic angle closure glaucoma, open angle glaucoma, and ocular hypertension; MicroStat, which has completed Phase III clinical trials for the treatment of mydriasis; MicroTears for the treatment of red eye and itch relief lubrication; and MicroPine for the treatment of progressive myopia. The company was formerly known as PGP Holdings V and changed its name to Eyenovia in May 2014. Eyenovia was founded in 2014 and is based in New York, New York.